Clinical Trial Detail

NCT ID NCT02639910
Title Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MorphoSys AG
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Tafasitamab-cxix + Venetoclax

Idelalisib + Tafasitamab-cxix

Age Groups: senior adult

No variant requirements are available.